Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase I

Treatment

Closed

18 and over

Pharmaceutical / Industry

CA182-003
NCT00207051

Trial Description

Summary

This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.

Eligibility Criteria

Inclusion Criteria:

Diagnosis of advanced or metastatic (tumor has spread) gastrointestinal malignancy

Feeling well other than cancer diagnosis (ie lab work, no infection, etc)

Available tumor tissue sample from prior surgery

Measurable disease on scans

4-6 weeks since prior therapy and recovered from the effects of prior therapy

Men and women, ages 18 and above

Women must not be pregnant or breastfeeding

Trial Contact Information

Trial Lead Organizations/Sponsors

Bristol-Myers Squibb Company - New York

Bristol-Myers Squibb

Study Director

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00207051
Information obtained from ClinicalTrials.gov on October 14, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.